Myovant Sciences Ltd Quick Ratio (MYOV) starting from the third quarter 2022 to third quarter 2021, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Myovant Sciences Ltd   (NYSE: MYOV)

Myovant Sciences Ltd 's Quick Ratio

MYOV's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the third quarter 2022, Quick Ratio deteriorated to 1.12 below Myovant Sciences Ltd 's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 459 other companies have achieved higher Quick Ratio than Myovant Sciences Ltd in third quarter 2022. While Quick Ratio total ranking in the third quarter 2022 has deteriorated compared to the prior quarter from 1818 to 2093.

Explain Quick Ratio?
How much Cash & cash equivalents MYOV´s has?
What are MYOV´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MYOV Quick Ratio (Dec 31 2022)
Q3		 (Sep 30 2022)
Q2		 (Jun 30 2022)
Q1		 (Mar 31 2022)
Q4		 (Dec 31 2021)
Q3
Y / Y Current Liabilities Change -8.65 % -6.2 % -26.44 % -10.77 % 6.73 %
Y / Y Cash & cash equivalent Change -48 % -39.73 % -37.39 % -36.61 % -29.24 %
Quick Ratio MRQ 1.12 1.48 1.58 1.73 1.96
MYOV's Total Ranking # 2093 # 1818 # 1552 # 1666 # 1555
Seq. Current Liabilities Change -2.36 % 11.25 % -9.88 % -6.69 % 0.26 %
Seq. Cash & cash equivalent Change -26.09 % 4.08 % -17.83 % -17.73 % -14.33 %



Quick Ratio third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 460
Healthcare Sector # 830
Overall Market # 2093


Quick Ratio Statistics
High Average Low
9.86 3.14 0.93
(Mar 31 2017)   (Mar 31 2020)




Financial Statements
Myovant Sciences Ltd 's Current Liabilities $ 246 Millions Visit MYOV's Balance sheet
Myovant Sciences Ltd 's Cash & cash equivalent $ 274 Millions Visit MYOV's Balance sheet
Source of MYOV's Sales Visit MYOV's Sales by Geography


Cumulative Myovant Sciences Ltd 's Quick Ratio

MYOV's Quick Ratio for the trailling 12 Months

MYOV Quick Ratio

 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months		 (Mar 31 2022)
12 Months		 (Dec 31 2021)
12 Months
Y / Y Current Liabilities TTM Growth -13.46 % -10.03 % 11.78 % 67.9 % 155.53 %
Y / Y Cash & cash equivalent TTM Growth -40.1 % -35.41 % -8.39 % 30.82 % 131.41 %
Quick Ratio TTM 1.47 1.69 1.91 1.96 2.13
Total Ranking TTM # 4660 # 4676 # 4671 # 4644 # 1507
Seq. Current Liabilities TTM Growth -2.33 % -1.64 % -7.42 % -2.69 % 1.53 %
Seq. Cash & cash equivalent TTM Growth -14.99 % -12.65 % -9.92 % -10.45 % -8.33 %

Quick ratio ranking by company, industry and sector >> Back to MYOV Financial Strength Comparisons >> Go to Compare MYOV Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in MYOV's Current Liabilities to $245.75 millions, cumulative Quick Ratio to 1.47 below the MYOV average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 582 other companies have achieved higher Quick Ratio than Myovant Sciences Ltd . While Quick Ratio overall ranking has improved so far to 4660, from total ranking during the twelve months ending second quarter 2022 at 4676.

Explain Quick Ratio?
How much Cash & cash equivalents MYOV´s has?
What are MYOV´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 583
Healthcare Sector # 1178
Within the Market # 4660


trailing twelve months Quick Ratio Statistics
High Average Low
7.48 2.77 1.47
(Dec 31 2017)   (Dec 31 2022)




Companies with similar Quick Ratio in the quarter ending Dec 31 2022, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2022 MRQ Cash & cash equivalentDec 31 2022 MRQ Current Liabilities
Polomar Health Services, Inc.  3.02 $ 0.226  Millions$ 0.075  Millions
Arcturus Therapeutics Holdings Inc   3.02 $ 391.883  Millions$ 129.884  Millions
Rafael Holdings Inc  3.01 $ 63.235  Millions$ 21.026  Millions
Ac Immune Sa  2.98 $ 34.180  Millions$ 11.481  Millions
Vanda Pharmaceuticals Inc   2.96 $ 135.029  Millions$ 45.551  Millions
Tvardi Therapeutics Inc   2.96 $ 63.741  Millions$ 21.540  Millions
Oncolytics Biotech Inc   2.96 $ 8.936  Millions$ 3.022  Millions
Tuhura Biosciences Inc   2.95 $ 11.780  Millions$ 3.990  Millions
Praxis Precision Medicines Inc   2.93 $ 100.489  Millions$ 34.345  Millions
Legend Biotech Corporation  2.90 $ 786.000  Millions$ 270.704  Millions
Metavia Inc   2.83 $ 33.364  Millions$ 11.784  Millions
Inventiva S a   2.83 $ 97.144  Millions$ 34.385  Millions
Alnylam Pharmaceuticals Inc   2.82 $ 2,164.284  Millions$ 767.915  Millions
Kala Bio inc   2.74 $ 70.495  Millions$ 25.685  Millions
Impel Pharmaceuticals Inc   2.74 $ 60.654  Millions$ 22.163  Millions
Vaccinex Inc   2.69 $ 6.391  Millions$ 2.373  Millions
Can fite Biopharma Ltd   2.67 $ 7.987  Millions$ 2.994  Millions
Beone Medicines Ltd   2.66 $ 3,869.760  Millions$ 1,454.894  Millions
Guardion Health Sciences Inc   2.66 $ 10.655  Millions$ 4.012  Millions
Inovio Pharmaceuticals Inc   2.61 $ 252.999  Millions$ 96.868  Millions
Aptevo Therapeutics Inc   2.60 $ 22.635  Millions$ 8.706  Millions
Vaxxinity Inc   2.59 $ 86.827  Millions$ 33.509  Millions
Eton Pharmaceuticals Inc   2.52 $ 16.305  Millions$ 6.461  Millions
Nucana Plc  2.50 $ 58.307  Millions$ 23.321  Millions
Horizon Therapeutics Public Limited Company  2.48 $ 2,357.588  Millions$ 951.966  Millions
Puretech Health Plc  2.46 $ 360.135  Millions$ 146.637  Millions
Bio Green Med Solution Inc   2.44 $ 18.300  Millions$ 7.511  Millions
Avenue Therapeutics Inc   2.43 $ 6.708  Millions$ 2.759  Millions
Aravive Inc   2.43 $ 53.689  Millions$ 22.112  Millions
Regeneron Pharmaceuticals Inc   2.41 $ 7,742.300  Millions$ 3,206.200  Millions

Date modified: 2026-09-26T07:31:36+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.